Rates of diagnosis and treatment are low, so there is a need for diagnostic tests and biomarkers for classification and ...

Cambridge-based Biogen is looking to the growth of its Alzheimer’s drug Leqembi to offset the decline of its multiple ...

It promises the benefits of a 10,000-step walk in just 30 minutes. No gym membership required. Just a pair of shoes and a ...

Over the past two centuries, vaccines have been critical for preventing infectious diseases. The World Health Organization estimates that vaccination prevents between 3 million and 5 million deaths ...

With "air pollution from fine particles linked to millions of premature deaths annually and [contributing] to climate change, ...

A new result shows that just about anyone at risk for Alzheimer’s – and that’s most of us – can change the trajectory of ...

The study included 2,469 participants from France, Japan and Finland who ... Study co-author Jenni Lehtisalo, a research fellow at the Finnish Institute for Health and Welfare, said the main takeaway ...

K-Bio showcases AI and protein removal advancements for dementia at Toronto conference Innovations in dementia treatment using AI and advanced drug delivery systems are at the forefront of discussions ...

Roche’s Alzheimer’s disease therapy has continued to show benefit for patients after 28 weeks in a long-term extension study. In the high-dose cohort from the ongoing Phase Ib/IIa Brainshuttle AD ...

ZUNVEYL was approved in July 2024 by the U.S. Food and Drug Administration (FDA) for the treatment of mild-to-moderate dementia of the Alzheimer's type in adults. As a new generation of ...

Virtual reality looks to be a useful tool on multiple fronts to help prevent falls among older residents, including those in ...

Dementia in Asia-Pacific is expected to triple by the end of the decade. In Asia's fast ageing populations, including ...